ResearcherUniversity Hospital FrankfurtActive in the last 2 years
Oliver Waidmann
Matched on ORCID iD 0000-0002-4143-5188; OpenAlex author ID A5004519568. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 30
2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 2 papers
Papers 6
- Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116… Co-author DOI 10.1007/s00432-024-05827-x↗
- Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pan… Co-author DOI 10.1016/s2468-1253(24)00197-3↗
- Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 stu… Co-author DOI 10.1016/j.esmoop.2022.100388↗
- Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study. Last author DOI 10.1159/000521258↗
- Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life resu… Co-author DOI 10.1002/ijc.33336↗
- Sequence therapy in metastatic pancreatic cancer. Co-author DOI 10.1055/a-0581-5640↗
Closest collaborators
The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Volker Kunzmann · 3 shared papers, 2022–2024 · strength 0.44
- Paper Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin… DOI 10.1007/s00432-024-05827-x↗
- Paper Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel aft… DOI 10.1016/s2468-1253(24)00197-3↗
- Paper Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the… DOI 10.1016/j.esmoop.2022.100388↗
- Volker Heinemann · 3 shared papers, 2022–2024 · strength 0.44
- Paper Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin… DOI 10.1007/s00432-024-05827-x↗
- Paper Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel aft… DOI 10.1016/s2468-1253(24)00197-3↗
- Paper Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the… DOI 10.1016/j.esmoop.2022.100388↗
- Stefan Hubert Boeck · 3 shared papers, 2018–2024 · strength 0.39
- Paper Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel aft… DOI 10.1016/s2468-1253(24)00197-3↗
- Paper Sequence therapy in metastatic pancreatic cancer. DOI 10.1055/a-0581-5640↗
- Paper Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the… DOI 10.1016/j.esmoop.2022.100388↗
- Dominik Paul Modest · 2 shared papers, 2024 · strength 0.33
- Paper Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin… DOI 10.1007/s00432-024-05827-x↗
- Paper Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel aft… DOI 10.1016/s2468-1253(24)00197-3↗
- Helmut Oettle · 2 shared papers, 2024 · strength 0.33
- Paper Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin… DOI 10.1007/s00432-024-05827-x↗
- Paper Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel aft… DOI 10.1016/s2468-1253(24)00197-3↗
- Thomas Jens Ettrich · 2 shared papers, 2022–2024 · strength 0.27
- Paper Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel aft… DOI 10.1016/s2468-1253(24)00197-3↗
- Paper Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the… DOI 10.1016/j.esmoop.2022.100388↗
- Frank Kullmann · 1 shared paper, 2024 · strength 0.16
- Larissa Henze · 1 shared paper, 2024 · strength 0.16
- Annika Kurreck · 1 shared paper, 2024 · strength 0.16
- Maximilian Reichert · 1 shared paper, 2024 · strength 0.16
- Michael Geißler · 1 shared paper, 2024 · strength 0.16
- Klara Dorman · 1 shared paper, 2024 · strength 0.16
- Anke Reinacher‐Schick · 1 shared paper, 2024 · strength 0.16
- Patrick Michl · 1 shared paper, 2024 · strength 0.16
- Jörg Trojan · 1 shared paper, 2022 · strength 0.15
- Alexander Queck · 1 shared paper, 2022 · strength 0.15
- Dirk‐Thomas Waldschmidt · 1 shared paper, 2018 · strength 0.12
- Uwe Pelzer · 1 shared paper, 2018 · strength 0.12
- Annalena Abendroth · 1 shared paper, 2022 · strength 0.11
- Michael Haas · 1 shared paper, 2022 · strength 0.11
- Andreas Wolfgang Berger · 1 shared paper, 2022 · strength 0.11
- Steffen Ormanns · 1 shared paper, 2022 · strength 0.11
- Stephan Krüger · 1 shared paper, 2022 · strength 0.11
- Sebastian Kobold · 1 shared paper, 2022 · strength 0.11
- Marianne Sinn · 1 shared paper, 2022 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.